Jun 14, 2024
Tibulizumab (ZB-106) was well tolerated and neutralized IL-17A and BAFF in a Phase 1 study in patients with Sjogren’s syndrome Preclinical data demonstrating the potential of dual inhibition of IL-17A and BAFF in a rheumatoid arthritis animal model support clinical development HENDERSON, Nev.
May 29, 2024
HENDERSON, Nev. --(BUSINESS WIRE)--May 29, 2024-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of senior management will participate in two investor
Apr 18, 2024
- Financing includes new and existing leading life sciences institutional investors - Strengthened balance sheet expected to fund operations through 2027 HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 18, 2024-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company
Apr 08, 2024
- Succeeds Founding CEO, Dr. Someit Sidhu, who will continue as a Board Director - Recognized as inspirational industry leader with exceptional R&D, commercial and global executive experience - Outstanding product development and commercialization track record across a number of leading I&I
Mar 04, 2024
HENDERSON, Nev. --(BUSINESS WIRE)--Mar. 4, 2024-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced that members of its senior management team will participate
Feb 02, 2024
HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 2, 2024-- Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced that members of its senior management team will participate